Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
INNOTECH, 27% Increase in Ordinary Profit, Record High for The First Time in Twenty Six Years, Dividend Raised by 5 Yen
9880 INNOTECH CORPORATION 【J-GAAP】
Earnings ReportINNOTECH CORPORATION <9880> [TSE Prime] announced its financial results after the market closed on May 14th (15:30). The consolidated ordinary profit for the fiscal year ended March 2026 expanded to 66.0% from the previous period to 2.91 billion yen. For the fiscal year ending March 2027, the consolidated ordinary profit is expected to grow by 27.1% to 3.70 billion yenExpected to reach record high profits for the first time in twenty six years. This will be the ninth consecutive term of revenue growth.
At the same time, the company has decided to increase the dividend this fiscal year to 130 yen, an increase of 5 yen from the previous fiscal year.
In the most recent three-month period, from January to March (4Q), the consolidated ordinary profit surged 2.1 times that of the same period last year, reaching 0.98 billion yen. The operating profit margin improved from 6.0% in the same period last year to 7.3%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 41,358 | 2,474 | 2,880 | 1,477 | 110.6 | 70 | May 10, 2024 | J-GAAP |
| Mar, 2025 | 41,977 | 1,887 | 1,754 | 1,200 | 89.5 | 70 | May 13, 2025 | J-GAAP |
| Mar, 2026 | 46,737 | 3,108 | 2,912 | 4,111 | 320.2 | 125 | May 14, 2026 | J-GAAP |
| YoY | +11.3% | +64.7% | +66.0% | +242.6% | +257.6% |
Full Year Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2026 Guidance | 46,500 | 3,000 | 2,800 | 4,000 | 328.6 | 125 | Mar 25, 2026 | J-GAAP |
| Mar, 2026 Results | 46,737 | 3,108 | 2,912 | 4,111 | 320.2 | 125 | May 14, 2026 | J-GAAP |
| Revision Rate | +0.5% | +3.6% | +4.0% | +2.8% | -2.5% |
Current Period Guidance
H1 Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Sep, 2025 | 21,601 | 1,137 | 752 | 574 | 43.8 | 35 | Nov 10, 2025 | J-GAAP |
| Apr - Sep, 2026 Guidance | ー | ー | ー | ー | - | 90 | May 14, 2026 | J-GAAP |
| YoY | - | - | - | - | - |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2025 | 41,977 | 1,887 | 1,754 | 1,200 | 89.5 | 70 | May 13, 2025 | J-GAAP |
| Mar, 2026 | 46,737 | 3,108 | 2,912 | 4,111 | 320.2 | 125 | May 14, 2026 | J-GAAP |
| Mar, 2027 Guidance | 50,000 | 3,700 | 3,700 | 4,850 | 398.4 | 130 | May 14, 2026 | J-GAAP |
| YoY | +7.0% | +19.0% | +27.1% | +18.0% | +24.4% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jan - Mar, 2025 | 12,055 | 722 | 474 | 205 | 15.3 | 6.0 | May 13, 2025 | J-GAAP |
| Apr - Jun, 2025 | 9,457 | 234 | 407 | 185 | 14.2 | 2.5 | Aug 8, 2025 | J-GAAP |
| Jul - Sep, 2025 | 12,144 | 903 | 345 | 389 | 29.7 | 7.4 | Nov 10, 2025 | J-GAAP |
| Oct - Dec, 2025 | 11,129 | 944 | 1,179 | 866 | 66.4 | 8.5 | Feb 9, 2026 | J-GAAP |
| Jan - Mar, 2026 | 14,007 | 1,027 | 981 | 2,671 | 208.0 | 7.3 | May 14, 2026 | J-GAAP |
| YoY | +16.2% | +42.2% | +107.0% | +1,202.9% | +1,259.7% |
Related Articles
Noile-Immune Biotech, Jan-Mar (1Q) Ordinary Profit Loss Narrows
SYNCLAYER, Jan-Mar (1Q) Ordinary Profit Decreases by 26%
SERENDIP HOLDINGS, 36% Increase in Ordinary Profit, Update Record High for Fourth Consecutive Term
Kamigumi, 8% Decrease in Ordinary Profit for The Current Fiscal Year, Increased Previous Year's Dividend by 20 Yen, Plan to Continue the 205 Yen Policy This Fiscal Year as Well
G-FACTORY, Jan-Mar (1Q) Ordinary Profit Loss Narrows
ALMEDIO, The Current Fiscal Year's Ordinary Loss to Narrow
General Oyster, Returning to Profitability This Year
COVER, Last Fiscal Year's Ordinary Profit Unexpectedly Declines, 1% Decrease in The Current Fiscal Year
RIBOMIC, The Current Fiscal Year's Net Income to Widen
ACSL, Jan-Mar (1Q) Ordinary Profit Loss Widens